B
Bull
Bull · 25%BNR
$4.42
Precio del escenario
$10.190
+0.194 (+1.90%)Al cierre
Loading chart…
- High
- 10.300
- Open
- 9.790
- VWAP
- 10.09
- Vol
- 29.18K
- Mkt Cap
- 66.17M
- Low
- 9.790
- Amount
- 294.49K
- EV/EBITDA, TTM
- 39.98
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
AI analysis of Burning Rock Biotech Limited (BNR)
buyBurning Rock Biotech Ltd (BNR) appears to be a good buy right now due to its recent upward price movement of 4.19% over the last five days and a current price of $10.19, which is close to its Fibonacci resistance level of $10.63. The stock's RSI of 57.18 indicates that it is not overbought, suggesting room for further growth. However, the main risk is its declining revenue trend, with a 14.7% year-over-year decrease in Q1 2026, which could impact future profitability.
Métricas de valoración
The current forward P/E ratio for Burning Rock Biotech Limited (BNR) is 0.00, compared to its 5-year average forward P/E of -4.47.
Alphio AI Price Scenarios for BNR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding BNR
Cronología de eventos
Noticias
5.007-02NewsfilterBurning Rock Founder Increases Company Shareholding
9.506-09seekingalphaBurning Rock Biotech Q1 Financial Results Analysis
- 5.004-02Newsfilter
Burning Rock CEO Yusheng Han Purchases $546K in ADSs, Signaling Confidence
- 9.503-12seekingalpha
Burning Rock Biotech Reports Q4 and Full Year 2025 Financial Results
8.002-12Barron'sSeeking Dividends? Explore Opportunities in Europe.
BNR FAQ — answered by Alphio AI
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).
Burning Rock Biotech Ltd (BNR) appears to be a good buy right now due to its recent upward price movement of 4.19% over the last five days and a current price of $10.19, which is close to its Fibonacci resistance level of $10.63. The stock's RSI of 57.18 indicates that it is not overbought, suggesting room for further growth. However, the main risk is its declining revenue trend, with a 14.7% year-over-year decrease in Q1 2026, which could impact future profitability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.